KR102448386B1 - 신경학적 장애를 치료하는 방법 - Google Patents

신경학적 장애를 치료하는 방법 Download PDF

Info

Publication number
KR102448386B1
KR102448386B1 KR1020167027090A KR20167027090A KR102448386B1 KR 102448386 B1 KR102448386 B1 KR 102448386B1 KR 1020167027090 A KR1020167027090 A KR 1020167027090A KR 20167027090 A KR20167027090 A KR 20167027090A KR 102448386 B1 KR102448386 B1 KR 102448386B1
Authority
KR
South Korea
Prior art keywords
acid
apoe4
pharmaceutical composition
compound
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020167027090A
Other languages
English (en)
Korean (ko)
Other versions
KR20160128391A (ko
Inventor
마틴 톨라
존 헤이
페트르 코시스
제레미 유
Original Assignee
알제온, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54145492&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR102448386(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 알제온, 인크. filed Critical 알제온, 인크.
Priority to KR1020227033161A priority Critical patent/KR102645633B1/ko
Publication of KR20160128391A publication Critical patent/KR20160128391A/ko
Application granted granted Critical
Publication of KR102448386B1 publication Critical patent/KR102448386B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
    • G16H10/20—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for electronic clinical trials or questionnaires
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/70—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to mental therapies, e.g. psychological therapy or autogenous training
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H40/00—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices
    • G16H40/20—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the management or administration of healthcare resources or facilities, e.g. managing hospital staff or surgery rooms

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Biophysics (AREA)
KR1020167027090A 2014-03-21 2015-03-23 신경학적 장애를 치료하는 방법 Active KR102448386B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020227033161A KR102645633B1 (ko) 2014-03-21 2015-03-23 신경학적 장애를 치료하는 방법

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461968595P 2014-03-21 2014-03-21
US61/968,595 2014-03-21
PCT/US2015/022058 WO2015143447A2 (en) 2014-03-21 2015-03-23 Methods for treating neurological disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020227033161A Division KR102645633B1 (ko) 2014-03-21 2015-03-23 신경학적 장애를 치료하는 방법

Publications (2)

Publication Number Publication Date
KR20160128391A KR20160128391A (ko) 2016-11-07
KR102448386B1 true KR102448386B1 (ko) 2022-09-28

Family

ID=54145492

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020167027090A Active KR102448386B1 (ko) 2014-03-21 2015-03-23 신경학적 장애를 치료하는 방법
KR1020227033161A Active KR102645633B1 (ko) 2014-03-21 2015-03-23 신경학적 장애를 치료하는 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020227033161A Active KR102645633B1 (ko) 2014-03-21 2015-03-23 신경학적 장애를 치료하는 방법

Country Status (19)

Country Link
US (3) US10471029B2 (enExample)
EP (2) EP3119911B1 (enExample)
JP (5) JP6588962B2 (enExample)
KR (2) KR102448386B1 (enExample)
CN (1) CN106170563A (enExample)
AU (1) AU2015230972B2 (enExample)
CA (1) CA2941415A1 (enExample)
DK (1) DK3119911T3 (enExample)
ES (1) ES2960625T3 (enExample)
FI (1) FI3119911T3 (enExample)
HR (1) HRP20231172T1 (enExample)
HU (1) HUE063369T2 (enExample)
LT (1) LT3119911T (enExample)
PL (1) PL3119911T3 (enExample)
PT (1) PT3119911T (enExample)
RS (1) RS64744B1 (enExample)
SI (1) SI3119911T1 (enExample)
SM (1) SMT202300369T1 (enExample)
WO (1) WO2015143447A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017044840A1 (en) * 2015-09-10 2017-03-16 Alzheon, Inc. Methods of treating neurodegenerative disorders in a particular patient population
EP3485892B1 (en) * 2016-07-13 2021-10-13 Mitos Co., Ltd. Composition for prevention or treatment of mild cognitive impairment or dementia containing hydrogen as active ingredient
CN114805211B (zh) 2017-03-21 2024-08-23 润佳（苏州）医药科技有限公司 同位素富集3-氨基-1-丙磺酸衍生物、药物组合物及其用途
CN110003058B (zh) 2018-01-04 2022-01-25 润佳（苏州）医药科技有限公司 3-((l-缬氨酰基)氨基)-3,3-二氘-1-丙磺酸晶型、制备方法及用途
CN110668980A (zh) * 2018-07-03 2020-01-10 浙江京新药业股份有限公司 一种2-取代的高牛磺酸衍生物
PL3829568T3 (pl) 2018-08-01 2024-03-25 Alzheon, Inc. Pochodne kwasu sulfopropanowego do leczenia zaburzeń neurodegeneracyjnych
LT3829563T (lt) * 2018-08-01 2025-02-25 Alzheon, Inc. 3-sulfopropano rūgštis neurodegeneracinėms ligoms gydyti
CN111170901A (zh) * 2018-11-13 2020-05-19 润佳（苏州）医药科技有限公司 3-((l-缬氨酰基)氨基)-1-丙磺酸晶型、制备方法及其用途
CN114269949A (zh) * 2019-06-17 2022-04-01 阿尔泽恩股份有限公司 用于治疗神经变性病症的方法
CN112791078B (zh) 2019-11-13 2022-12-06 润佳（苏州）医药科技有限公司 同位素富集的3-氨基-1-丙磺酸及其衍生物的用途
US20250345298A1 (en) 2022-04-28 2025-11-13 Alzheon, Inc. Apoe4 correctors and methods of use
CN120641092A (zh) 2022-12-02 2025-09-12 阿尔泽恩股份有限公司 用于用曲米沙特治疗神经变性病症的方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994009155A1 (en) 1992-10-13 1994-04-28 Duke University Methods of detecting alzheimer's disease
US20060079578A1 (en) 2003-06-23 2006-04-13 Julie Laurin Pharmaceutical formulations of amyloid inhibiting compounds
US20080146642A1 (en) * 2006-10-12 2008-06-19 Xianqi Kong Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
US20050031651A1 (en) 2002-12-24 2005-02-10 Francine Gervais Therapeutic formulations for the treatment of beta-amyloid related diseases
US20070010573A1 (en) * 2003-06-23 2007-01-11 Xianqi Kong Methods and compositions for treating amyloid-related diseases
US20050142191A1 (en) 2003-06-23 2005-06-30 Neurochem (International) Limited Pharmaceutical formulations of amyloid inhibiting compounds
WO2005060393A2 (en) 2003-08-11 2005-07-07 California Institute Of Technology Microfluidic large scale integration
US20100183513A1 (en) 2006-11-24 2010-07-22 Wolfgang Froestl N-(methyl) -1h-pyrazol-3-amine, n-(methyl)-pyridin-2-amine and n-(methyl)-thiazol-2-amine derivatives for the treatment of diseases associated with amyloid or amyloid-like proteins, like e.g. alzheimer's
US20120009125A1 (en) 2010-07-06 2012-01-12 Lombard Jay L Apoe4 and apoj biomarker-based prevention and treatment of dementia
DK2605655T3 (en) 2010-08-19 2019-02-04 Buck Institute For Age Res METHODS OF TREATING SMALL COGNITIVE DISABILITY (MCI) AND RELATED DISORDERS
JP6424210B2 (ja) 2013-05-06 2018-11-14 バクスアルタ インコーポレイテッド プールされた免疫グロブリンｇを用いたアルツハイマー病の亜集団の治療
BR112016018170A2 (pt) * 2014-02-08 2018-02-20 Genentech, Inc. métodos para tratar doença de alzheimer
WO2017044840A1 (en) 2015-09-10 2017-03-16 Alzheon, Inc. Methods of treating neurodegenerative disorders in a particular patient population
US20180250249A1 (en) 2016-02-02 2018-09-06 Alzheon, Inc. Methods of treating neurodegenerative disorders in a particular population

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994009155A1 (en) 1992-10-13 1994-04-28 Duke University Methods of detecting alzheimer's disease
US20060079578A1 (en) 2003-06-23 2006-04-13 Julie Laurin Pharmaceutical formulations of amyloid inhibiting compounds
US20080146642A1 (en) * 2006-10-12 2008-06-19 Xianqi Kong Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Caltagirone et al., "The potential protective effect of tramiprosate (homotaurine) against Alzheimer's disease: a review.", Aging clinical and experimental research v.24 no.6 , pp.580 - 587, 2012. 1부.*

Also Published As

Publication number Publication date
JP2019065044A (ja) 2019-04-25
AU2015230972B2 (en) 2021-05-27
US20230087041A1 (en) 2023-03-23
CA2941415A1 (en) 2015-09-24
EP4289820A3 (en) 2024-03-13
US20170172952A1 (en) 2017-06-22
ES2960625T3 (es) 2024-03-05
PL3119911T3 (pl) 2024-01-22
AU2015230972A1 (en) 2016-09-15
EP4289820A2 (en) 2023-12-13
PT3119911T (pt) 2023-11-03
HUE063369T2 (hu) 2024-01-28
SMT202300369T1 (it) 2023-11-13
EP3119911A4 (en) 2017-12-13
HRP20231172T1 (hr) 2024-01-05
LT3119911T (lt) 2023-10-10
KR102645633B1 (ko) 2024-03-11
JP2020109123A (ja) 2020-07-16
DK3119911T3 (da) 2023-10-30
JP2022159555A (ja) 2022-10-17
JP2017511377A (ja) 2017-04-20
KR20160128391A (ko) 2016-11-07
RS64744B1 (sr) 2023-11-30
FI3119911T3 (fi) 2023-09-27
CN106170563A (zh) 2016-11-30
JP6588962B2 (ja) 2019-10-09
US10471029B2 (en) 2019-11-12
SI3119911T1 (sl) 2023-12-29
KR20220136476A (ko) 2022-10-07
EP3119911B1 (en) 2023-08-09
EP3119911A2 (en) 2017-01-25
WO2015143447A3 (en) 2016-01-14
JP2025022992A (ja) 2025-02-14
US20200101031A1 (en) 2020-04-02
WO2015143447A2 (en) 2015-09-24

Similar Documents

Publication Publication Date Title
KR102448386B1 (ko) 신경학적 장애를 치료하는 방법
TWI633887B (zh) 用於預防及／或治療多囊性腎臟病之藥物
US20070190043A1 (en) Use of a topical medicament comprising riluzole
JP2022513556A (ja) κオピオイド受容体作動薬の経口製剤
US10870678B2 (en) Chiral peptides
CN101208091A (zh) 促进口腔吸收的麻醉药的固体药制剂
ES2303314T3 (es) Formulaciones de liberacion prolongada de dipiridamol y procedimiento para su preparacion.
JP2016521249A (ja) リナクロチド組成物
ZA200600159B (en) Novel solid pharmaceutical composition comprising amisulpride
JP2017533967A (ja) システアミン組成物を用いるハンチントン病の処置方法
JP2020125330A (ja) 縮合アミノジヒドロチアジン誘導体の医薬組成物
CN106061494A (zh) 可用于治疗阿片样物质诱导的功能障碍的鸟苷酸环化酶的激动剂
KR20180132955A (ko) 갑상샘 호르몬 또는 이의 유사체를 제공하는 조성물 및 방법
US20240423995A1 (en) C-kit inhibitors and uses for treating and preventing inflammatory conditions
CN119371651B (zh) 一种靶向Bcr-Abl的自组装纳米材料的制备方法及其用途
CN115103675B (zh) 用于治疗和预防中枢神经系统疾病的化合物
RS59064B1 (sr) Antimikrobijalne kompozicije sa šumećim agensima
CN111902138A (zh) 在乙酰胆碱酯酶抑制剂治疗失去反应的患者中对阿兹海默氏病的基于巴氯芬和阿坎酸的治疗
AU2008200878A1 (en) Use of a topical medicament comprising riluzole
JP2013032289A (ja) ワックス安定製剤
TW201929850A (zh) 醫藥組成物於製備預防或治療不正常乙型-澱粉樣蛋白聚集類疾病之藥物上之用途

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

X091 Application refused [patent]
T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

X701 Decision to grant (after re-examination)
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4